cbd stocks robinhood

Cbd stocks robinhood

HEXO sports one of the most attractive valuations among Canadian cannabis companies. Its shares trade at less than seven times trailing-12-month sales.

Cronos Group (NASDAQ:CRON) is another Canadian cannabis producer with a connection to a tobacco giant: Altria owns 45% of Cronos. The big investment by Altria gave Cronos a nice cash stockpile to use in expanding.


Tilray (NASDAQ:TLRY) recently closed its merger with Aphria to create, in its words, “the world’s largest global cannabis company.” The company ranks as a market leader in Canada’s adult-use market as well as Germany’s medical cannabis market.

The chief problem for Sundial is that its sales continue to decline. In its latest quarter, the company reported that its revenue slid 29% year over year and 30% quarter over quarter. However, Sundial posted positive adjusted EBITDA thanks to its investments.

5. Cronos Group

Thanks to its 2019 acquisition of Lord Jones, Cronos has a strong presence in the U.S. CBD products market. It also has another key partnership with U.S.-based Ginkgo Bioworks to develop cannabinoids using fermentation processes.

Cbd stocks robinhood

Top Canadian Marijuana Stocks To Watch In August

With operations in Canada, the US, Europe, Australia, and Latin America Tilray, Inc. is a leading global cannabis consumer packaged goods company. The company has undergone one of the biggest mergers in the Canadian market to become one of the largest revenues producing cannabis companies worldwide. Tilray is positioning itself to enter the US market and is also expanding its international presence. Recently, the company completed its first harvest and delivery of medical cannabis grown in Germany. This marks the first cannabis cultivated at Tilray’s state-of-the-art 6000 square meters grow facility in Germany.

Canopy Growth Corporation

Aurora Cannabis Inc. is a company that produces and distributes medical cannabis products globally. In May Aurora announced its third-quarter fiscal 2021 results with domestic medical net revenue at $26.9 million. Also important, the company had strong international medical revenue of $9.4 million. For the third quarter of fiscal 2021, the company has total cannabis net revenue of $58.4 million. Recently the company announced its entry into the US market through the acquisition of Reliva a CBD producing company in America. Aurora also expanded its San Rafael ’71 portfolio with the launch of 3 new proprietary cultivars.

In the meantime, the company has established CBD products and infused beverages that could be large revenue producers across the Canadian and American markets. On July 28 th Tilray reported its 2021 fiscal year and q4 results with net revenue up 27% year over year to $513 million. As a result, the company produced a net income of $33.6 million an adjusted EBITDA of $12.3 million and completed its merger with Aphria Inc. The company grew revenue by 55% in Q4 and holds the #1 share in Canada.